Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who will also serve on the board’s audit committee.
She said: “I am honoured to join Editas Medicine’s board of directors.
“Editas is on the forefront of a new era in medicine, and I look forward to working with the team and helping guide the company in the coming years.”
Dr Hopfield has more than two decades worth of experience in the medical and healthcare fields and she has held management positions at Merck Sharp & Dohme (MSD) in clinical development, outcomes research and marketing.
Katrine Bosley, president and chief executive officer of Editas Medicine, said: “With her wide range of scientific and business expertise, Jessica brings great strategic acumen to Editas Medicine, and I am pleased to welcome her to our board of directors.
“Her contributions as a director on our board will be vital as work towards achieving our long-range goals for the year 2022 and vision for advancing Editas Medicine as a leading genome editing company.”